Last reviewed · How we verify
polyethylene glycol alone
Polyethylene glycol (PEG) is an osmotic laxative that draws water into the intestinal lumen to soften stool and promote bowel movements.
Polyethylene glycol (PEG) is an osmotic laxative that draws water into the intestinal lumen to soften stool and promote bowel movements. Used for Constipation, Bowel preparation prior to colonoscopy or other gastrointestinal procedures.
At a glance
| Generic name | polyethylene glycol alone |
|---|---|
| Also known as | NIFLEC alone |
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Drug class | Osmotic laxative |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
PEG is a non-absorbable polymer that creates an osmotic gradient in the colon, increasing stool water content and facilitating evacuation. It works locally in the gastrointestinal tract without systemic absorption, making it a safe option for bowel preparation and constipation relief. The mechanism is purely physical and osmotic rather than pharmacological.
Approved indications
- Constipation
- Bowel preparation prior to colonoscopy or other gastrointestinal procedures
Common side effects
- Nausea
- Abdominal bloating or distension
- Abdominal cramping
- Vomiting
- Diarrhea
Key clinical trials
- A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body (PHASE1)
- Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery (PHASE4)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy (PHASE3)
- Mobilization and Outcomes After Venous Closure
- Clinical Trial on Bowel Preparation Comparing Mannitol 100g to Plenvu Both in a Same Day Regimen (CLEARWAY) (PHASE3)
- Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
- Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: